|
|
|
|
| LEADER |
04254nmm a2200553 u 4500 |
| 001 |
EB001938403 |
| 003 |
EBX01000000000000001101305 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210123 ||| eng |
| 020 |
|
|
|a 9781306178280
|
| 020 |
|
|
|a 1907568123
|
| 020 |
|
|
|a 1306178282
|
| 020 |
|
|
|a 1908818085
|
| 020 |
|
|
|a 9781908818089
|
| 050 |
|
4 |
|a K1519.D78
|
| 100 |
1 |
|
|a Bouchard, Ron A.
|
| 245 |
0 |
0 |
|a Patently innovative
|b how pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs
|c Ron A. Bouchard
|
| 260 |
|
|
|a Cambridge, U.K.
|b Woodhead Pub.
|c 2012
|
| 300 |
|
|
|a 1 volume
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references and index
|
| 505 |
0 |
|
|a 5.5 Summary and conclusionsNotes; 6 Implications of empirical data: are pharmaceutical linkage regulations a success?; 6.1 Introduction; 6.2 Debate preceding Bill C-91; 6.3 'Original policy intent'; 6.4 'Patent-specific' analysis; 6.5 Statutory interpretation; 6.6 Revisiting the empirical data; 6.7 Summary and conclusions; Notes; 7 Future directions: testable hypotheses and evolution toward global pharmaceutical linkage; 7.1 Hypotheses regarding cluster-based drug development; 7.2 Globalization of pharmaceutical linkage; Notes; Index
|
| 505 |
0 |
|
|a Cover; Dedication; Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs; Copyright; Contents; Acknowledgements; List of figures and tables; List of abbreviations; About the author; 1 Introduction; 1.1 The emergence of global pharmaceutical linkage; 1.2 Canadian pharmaceutical linkage regulations; 1.3 Organization; Notes; 2 Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy; 2.1 Drug approval; 2.2 Patents; 2.3 Linkage regulations; 2.4 IPR rights and innovation policy; Notes
|
| 505 |
0 |
|
|a 3 Empirical analysis of drug approval3.1 Introduction; 3.2 Analysis; 3.3 Results; 3.4 Discussion; 3.5 Interpretation of data; 3.6 Study limitations; 3.7 Assessing the lifecycle approach: the long view; 3.8 Government as representative public agent; 3.9 Summary and conclusions; Notes; 4 Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.4 Discussion; Notes; 5 Empirical analysis of drug patenting in multiple high-value cohorts; 5.1 Introduction; 5.2 Methods; 5.3 Results; 5.4 Discussion
|
| 653 |
|
|
|a Médicaments / Développement
|
| 653 |
|
|
|a Drug development / Canada
|
| 653 |
|
|
|a Médicaments / Développement / Canada
|
| 653 |
|
|
|a Drugs / Patents
|
| 653 |
|
|
|a Drug development / fast
|
| 653 |
|
|
|a Patent extensions / http://id.loc.gov/authorities/subjects/sh85098643
|
| 653 |
|
|
|a Médicaments / Canada / Brevets d'invention
|
| 653 |
|
|
|a Drugs / fast
|
| 653 |
|
|
|a Brevets d'invention / Prolongation de la durée / Canada
|
| 653 |
|
|
|a Médicaments / Brevets d'invention
|
| 653 |
|
|
|a Canada / fast / https://id.oclc.org/worldcat/entity/E39PBJkMHVW4rfVXPrhVP4VwG3
|
| 653 |
|
|
|a Drug development / http://id.loc.gov/authorities/subjects/sh97007921
|
| 653 |
|
|
|a Brevets d'invention / Prolongation de la durée
|
| 653 |
|
|
|a Patent extensions / Canada
|
| 653 |
|
|
|a Drugs / Canada / Patents
|
| 653 |
|
|
|a Patent extensions / fast
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b OREILLY
|a O'Reilly
|
| 490 |
0 |
|
|a Woodhead publishing series in biomedicine
|
| 776 |
|
|
|z 9781907568121
|
| 776 |
|
|
|z 1306178282
|
| 776 |
|
|
|z 9781306178280
|
| 856 |
4 |
0 |
|u https://learning.oreilly.com/library/view/~/9781907568121/?ar
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 346.0486
|
| 520 |
|
|
|a Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products. Includes empirical research to relate innovation to drug lawA multidisciplinary approach is taken, including the intersection of IP (intellectual property) law, drug law an
|